GlassScriptPhysician profile
Brianna Ferrell
NPI 1811782410
$2,087.21
in general payments reported to CMS, 2019-2025
33 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.28 |
| Education | $475.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $269.75 | 2025 | Xtandi, Vyloy, Padcev |
| Daiichi Sankyo INC. | $211.16 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $178.32 | 2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $165.33 | 2025 | Reblozyl |
| Incyte Corporation | $147.64 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $91.35 | 2025 | |
| Seagen INC. | $77.99 | 2025 | |
| Janssen Biotech, INC. | $76.15 | 2025 | Rybrevant, Darzalex |
| Pfizer INC. | $68.67 | 2025 | |
| Genentech USA, INC. | $68.11 | 2025 | Itovebi |
| Bayer Healthcare Pharmaceuticals INC. | $61.32 | 2025 | |
| Pharmacosmos Therapeutics INC. | $55.76 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $55.62 | 2025 | Jemperli, Zejula, Ojjaara |
| Sobi, INC | $53.31 | 2025 | |
| Servier Pharmaceuticals LLC | $50.32 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.31 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $37.36 | 2025 | Tagrisso |
| Dendreon Pharmaceuticals LLC | $34.76 | 2025 | Provenge |
| Novocure INC. | $33.79 | 2025 | Optune Lua (Novottf-200t) |
| Array Biopharma INC | $30.89 | 2025 | Braftovi, Lorbrena, Mektovi |
| Geron Corporation | $28.15 | 2025 | Rytelo |
| Emd Serono, INC. | $26.77 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $25.96 | 2025 | Onivyde |
| Tersera Therapeutics LLC | $24.75 | 2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $22.27 | 2025 | |
| Beone Medicines USA, INC. | $22.11 | 2025 | Brukinsa |
| Pharmaand Gmbh | $21.12 | 2025 | Rubraca |
| Pharmaessentia USA Corporation | $19.45 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $18.93 | 2025 | Ultomiris |
| Genzyme Corporation | $18.75 | 2025 | |
| Tolmar, INC. | $18.59 | 2025 | Eligard, Rubraca |
| Puma Biotechnology, INC. | $15.34 | 2025 | |
| Adaptive Biotechnologies Corporation | $14.11 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.